

Purvalanol A, CDK inhibitor

Catalog	Unit
TBI2868-5MG	5 mg
TBI2868-25MG	25 mg

Product Details

Formal Name: (2R)-2-[[6-[(3-Chlorophenyl)amino]-9-(1-methylethyl)-9H-purin-2-yl]amino]-3-methyl-1-butanol

Alternate Names: NG-60

Molecular Formula: C₁₉H₂₅ClN₆O

Formula Weight: 388.89

CAS Number: 212844-53-6


Purity: >98%

Formulation: powder

Solubility: Soluble in DMSO (up to 35 mg/ml)

Storage: -20°C

Stability: ≥ 1 year.



Applications

CDK inhibitor

Functions

Cyclin-dependent kinase inhibitor. IC₅₀s= 4, 70, 35, 75 and 850 nM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E, cdk5/p35 and cdk4/cyclin D1 and respectively. Reversibly arrests synchronized cells in G1 and G2 phase. Induces ER stress-mediated apoptosis and autophagy in colon cancer cells. Suppresses Src-mediated transformation by inhibiting both CDKs and c-Src. In cells transformed with MYC, purvalanol A rapidly down-regulates survivin expression and induces MYC-dependent apoptosis. Cell permeable.

Application Procedures

First dissolved in DMSO (up to 35 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20°C for up to 2 months.

For research use only.